Somatostatin Receptor 2 antagonists (SSTR2a) increase glucagon counter-regulation to hypoglycemia in various rodent models of type-1 diabetes mellitus. Here we investigated the efficacy of SSTR2a in improving glucagon counter-regulation in a rat model of type-2 diabetes mellitus (T2DM). For this, male Sprague Dawley rats (n=18) were given a high fat diet for 3 weeks, followed by low-dose streptozotocin exposure (35 mg/kg, IP) to induce T2DM. Rats were then divided into SSTR2a treatment (PRL-2903, 10 mg/kg) or vehicle (n=9 for each) 1-hour before insulin-induced hypoglycemia (3 IU/kg NovoRapid). This process was repeated 1 week later in a cross-over design, with the data pooled over SSTR2a and vehicle treatments. A group of normal-chow-fed rats (n=3) served as nondiabetic controls. Mean blood glucose levels were higher at 20, 30, 40, and 50 minutes post insulin administration in the T2DM rats treated with PRL-2903, as compared to vehicle (p ≤ 0.05). The number of T2DM rats that developed biochemical hypoglycemia (blood glucose ≤ 3.5 mmol/L) tended to be less with PRL-2903 (5/18) vs. vehicle (9/18). Compared with vehicle treatment, PRL-2903 promoted higher plasma glucagon counter-regulation, as indicated by area under curve (AUC) analysis (p < 0.05). Thus, SSTR2a treatment improves the attenuated glucagon response to hypoglycemia in T2DM rats.


M. Nejad-Mansouri: None. P. Zaree Bavani: None. J. Aiken: None. N.C. DSouza: None. E.G. Hoffman: None. R. Liggins: None. M. Riddell: Advisory Panel; Self; Xeris Pharmaceuticals, Inc. Research Support; Self; Dexcom, Inc. Speaker’s Bureau; Self; Insulet Corporation, Medtronic MiniMed, Inc. Stock/Shareholder; Self; Zucara Therapeutics Inc.


National Research Council Canada; Zucara Therapeutics

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at